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The release of a GPI-linked oncofetal protein (PLAP) from HEp-2 cells has been studied as an indicator of endogenous PI-specific PLC activation. 
A non-hydrolysable GTP analogue, EGF and insulin all produced a dose-dependent release of PLAP from these cells. This indicates that an increase 
in PLC activity following either growth factor binding or G protein activation may cause cellular release of PLAP. 
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1. INTRODUCTION 
Human placental syncytiotrophoblast after the first 
trimester of pregnancy expresses placental-type alkaline 
phosphatase (PLAP) on its cell surface together with 
several growth factor receptors [1,2]. PLAP is a dimeric 
130 kDa sialoglycoprotein that is also expressed by 
many tumour cell lines (including HEp-2) and solid 
tumour tissues [1,3-51. PLAP has been shown to be one 
of an increasing number of cell surface molecules an- 
chored to the outer leaflet of the plasma membrane by 
a glycosyl-phosphatidylinositol (GPI)-linkage that can 
be specifically cleaved by bacterial phosphatidyl- 
inositol-specific phospholipase-C (b-PLC) [4,7]. 
recent evidence suggests hat an alternative mechanism 
for PLC activation is through the PLC phosphorylation 
by growth factor receptor-tyrosyl kinase (RTK) com- 
plexes [ 1 l- 131. We have studied PLAP release as an in- 
dicator of endogenous PLC activation through both 
RTK and G protein activation in the HEp-2 human car- 
cinoma cell line. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Many tumour cell lines are known to express high 
numbers of growth factor receptors (e.g. epidermal 
growth factor (EGF) receptor on HEp-2 cells (Roberts, 
J.M., unpublished observations)). The EGF, insulin 
and platelet-derived growth factor (PDGF) receptor are 
among the best characterised and all possess ligand- 
induced intrinsic tyrosine-specific kinase activity, which 
is an essential part of their signal transduction 
mechanisms [6]. An important early mediator of in- 
creased cellular phosphatidylinositol (PI) turnover 
following the interaction of cell surface growth factor 
receptors with their corresponding ligand is the activa- 
tion of endogenous cellular PI-hydrolysing enzymes, 
collectively termed PLC [8]. PLC may be coupled to 
certain cell surface receptors by a group of G proteins 
[91, such has been demonstrated for vasopressin, 
bombesin, bradykinin, (Y thrombin, thyrotropin- 
releasing hormone and angiotensin II 19, lo]. However, 
The HEp-2 (human laryngeal carcinoma) cell line was maintained 
in minimal essential medium containing 10% fetal calf serum, 100 
W/ml penicillin and 100 fig/ml streptomycin (Gibco). HEp-2 cells 
were grown to confluence in 6-well plates (approximately 1x lo6 cells 
per well) and then incubated in serum-free medium for 2 h before use. 
Cells were then washed 3 x in Hanks’ balanced salt solution (HBBS), 
pH 7.4, containing 20 mM Hepes. A well of cells was trypsinised and 
counted on the day of each experiment to give a cell count. 
2.2 Treatment with b-PLC 
Hep-2 cells were incubated with 0.025 U/ml (lowest optimum con- 
centration) of purified PI-specific PLC (PI-PLC) from Bacillus thur- 
ingiensis (Peninsular Laboratories, Merseyside) in isotonic 
phosphate-buffered saline (PBS), pH 7.4, for 1 hour at 37”C, or with 
a PLC specific for phosphatidylcholine from Clostridiumperfringens 
(Sigma type XII), or buffer alone. The incubation medium was 
microfuged at 11 OOOxg for 10 min and the supernatant stored at 
- 20°C or assayed for PLAP. The PLAP (mu/ml) released into the 
buffer alone was subtracted as background from all other experimen- 
tal values when calculating results. 
2.3. Incubation with GTP analogues 
Correspondence address: J.M. Roberts, Department of Im- 
munology, University of Liverpool, PO Box 147, Liverpool L69 3BX, 
UK 
GTPrS tetralithium salt and GDP@S trilithium salt (Sigma) were 
stored at -20°C. HEp-2 cells were treated with 25 pg/ml freshly 
dissolved digitonin in HBBS/Hepes for 5 min at room temperature to 
permealyse the cells. This was followed by 3 washes with 
HBBS/Hepes and then the cells were incubated with HBBS/Hepes 
alone, GTPyS or GDPflS for 30 min at 37°C. The incubation medium 
was collected as for PLC treatment. 
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2.4. Incubation with growth factors 
Following incubation with serum-free medium, cells were washed 
and incubated with insulin (range 25 ,&nI to 10 ng/ml, porcine, 
Sigma), EGF (250- 1 ng/ml, human recombinant, Boerhinger 
Mannheim) or PDGF (lOO- 1 ng/ml, porcine Boerhinger Mannheim) 
in 1 ml HBBWHepes at 37°C for 2 h. Cells incubated in buffer alone 
were used as controls. The incubation medium was collected and 
assayed for PLAP as before. 
2.5. PLAP assay 
PLAP release was measured by a sensitive enzyme immunoassay 
using the H317 murine monoclonal antibody (mAb) specific for 
human PLAP or the H3 15 mAb specific for both PLAP and PLAP- 
like enzymes [l, 14,151. Assays were standardised using known 
amounts of purified human PLAP (Sigma). Undiluted cell-free super 
natants (150 rl), with Tween 20 added to 0.05% were assayed fo 
PLAP in triplicate. 
3. RESULTS 
3.1. PLC-induced PLAP release from HEp-2 cells 
Treatment of HEp-2 cells with PI-specific PLC 
released significant amounts of PLAP into the cell 
culture supernatant compared with controls (Table I). 
When the released material was concentrated 6-fold and 
applied to SDS-PAGE gels under non-reducing condi- 
tions and Western blotted, a single 115 kDa band (see 
[3]) at the same position as that for the isolated PLAP 
standard was identified as alkaline phosphatase by a 
calorimetric reaction [3] (data not shown). This con- 
firmed earlier work using 3H-fatty acid-labelled HEp-2 
cells, where b-PLC released ‘H-labelled PLAP that 
could be immunoprecipitated with a specific 
monoclonal antibody and ran as a 66 kDa monomer on 
reducing SDS-PAGE gels [4]. 
3.2. PLAP release following treatment with a GTP 
analogue 
Treatment of permealised HEp-2 cells with the non- 
hydrolysable analogue GTPyS produced a dose de- 
pendent increase in PLAP release (Fig. 1). A concentra- 
tion of 100 PM GTPyS or greater was required to pro- 
duce a significant increase in PLAP release. In com- 
parison, treatment with GDPpS had little effect but did 
give values consistently higher than buffer alone that 
were about 20-25070 of PLAP released following treat- 
ment with an optimal concentration of GTPyS. The ac- 
tual amount of PLAP released calculated as mu/lo6 
cells was variable between experiments (which appeared 
to be partly due to deterioration of the GTP analogue 
stock), but was always in the range of 0.8-5.0 mu/ml. 
Table 1 
PLAP release following the treatment of HEp-2 cells with PLC 
PLAP released mU/106cells, + SE 
PBS alone 0.94* 0.27 (n=6) 
PI-PLC 49.0 tl1 (n=6) 
PC-PLC 1.34* 0.37 (n=5) 
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Fig. 1. The effect of GTPyS (o---o) and GDP@S (a) on 
PLAP release from digitonin-permealysed HEp-2 cells. The figure 
represents PLAP released as a % of the maximum GTPyS-stimulated 
PLAP release, the results being the mean of 5 experiments. Error bars 
are +SE. 
3.3. PLAP release following treatment with growth 
factors 
The incubation of serum-starved HEp-2 cells with in- 
sulin or EGF produced a small but reproducibly 
measurable release of PLAP. PDGF in the range l-100 
ng/ml had no effect. The PLAP release following EGF 
or insulin treatment was dose-dependent and reached a 
plateau at 50 ng/ml EGF and 10 pg/ml insulin (Fig. 2a 
and b, respectively). The greatest release of PLAP was 
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Fig. 2. Dose-response curves for (a) EGF- and (b) insulin-stimulated 
release of PLAP from intact HEp-2 cells. Error bars are + SE, n = 5. 
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measured following treatment with EGF. In some ex- 
periments, half of the microfuged supernatant collected 
following treatment with EGF or insulin was filtered 
through 0.22 PMillipore filters to remove any remaining 
cell membrane contaminants. Both filtered and un- 
filtered samples gave the same values for PLAP release. 
PLAP release from HEp-2 cells following growth 
factor treatment was less than that observed when cells 
were treated with GTP$S, the highest release with EGF 
being 0.82kO.5 mu/lo6 cells and that with GTPrS 
2.1+ 1.6 mu/lo6 cells. This is in the range of 1.6-4.3% 
of surface PLAP releasable by exogenous b-PLC. 
4. DISCUSSION 
High levels of PLAP are found on the surface of 
human placental syncytiotrophoblast as well as certain 
tumour tissues and cell lines [I ,3-51, while only trace 
amounts are found in normal, non-placental reproduc- 
tive or other tissues [14]. PLAP is released into the 
maternal circulation as gestation progresses [l] and is 
also elevated in the serum of cigarette smokers and pa- 
tients with PLAP-expressing tumours [ 1,161. However, 
the physiological significance of PLAP expression and 
release remains obscure. In this study, we have in- 
vestigated whether PLAP can be released from a 
tumour cell line by agents known to be capable of ac- 
tivating endogenous PLC as part of intracellular 
signalling mechanisms. 
Treatment of permeabilised cells with non- 
hydrolysable analogues of GTP can permanently ac- 
tivate G proteins coupled to PLC, resulting in sustained 
hydrolysis of PI [9]. We have shown that a non- 
hydrolysable GTP analogue consistently released a 
small percentage of the total PLAP from permeabilised 
HEp-2 cells, indicating that activation of membrane- 
associated PLC by GTP could cleave this GPI-linked 
protein from the plasma membrane. The observation 
that GDPpS also induced a small increase in PLAP 
release over control values, although considerably less 
than that with GTP-yS, does not appear consistent with 
the concept that GDP analogues inactivate G proteins 
and inhibit PI turnover. However, in this system 
GDP/IS may inactivate a PLC-inhibitory G protein, 
releasing PLC from inhibitory control and resulting in 
raised PLC activity [16]. An increase of PLC activity 
with GDPpS was also recently reported in rat 
hepatocyte plasma membrane preparations [171. 
Insulin, PDGF and EGF receptors have cytoplasmic 
tyrosyl kinase domains capable of stimulating PI 
turnover and activation of PLC in rapid response to 
ligand binding [ 18-201. EGF and PDGF RTKs can 
directly phophorylate a PLC enzyme, PLC-II, sug- 
gesting the mechanism for their activation of this 
membrane-associated nzyme [ 1 l-131. In this study, the 
incubation of HEp-2 cells with either insulin or EGF in- 
duced PLAP release from intact cells, indicating that 
PLC had been activated. This was not observed with 
PDGF treatment, but the expression of PDGF recep- 
tors by HEp-2 cells has not been confirmed. Insulin is 
unusual in that it promotes hydrolysis of a PI-glycan 
rather than PI 4,5biphosphate by activation of a 
specific PLC to yield two products, a PI-glycan polar 
head group and diacylglycerol [21]. In this case, the 
growth factor RTK complex might induce tyrosine 
phosphorylation of G proteins, as has been 
demonstrated for insulin in vitro [22], although this has 
not been reported in vivo. Insulin has also been shown 
to induce the selective release of a number of other GPI- 
anchored proteins, including lipoprotein lipase [23], 
non-placental alkaline phosphatase [24] and two 
unidentified proteins of 35 kDa and 130 kDa 1251 from 
insulin-sensitive cell lines, but the effect of EGF on 
release of these proteins has not been studied. 
Only a small percentage of the total HEp-2 cell sur- 
face PLAP is released following incubation with EGF 
or insulin. Growth factor binding may activate only a 
small population of the total cellular PLC, or only a 
small proportion of activated PLC molecules may be 
able to release GPI-linked proteins. It would be of in- 
terest to assess the release of other GPI-linked cells sur- 
face proteins to determine whether any are more 
susceptible to release by growth factors than others, as 
suggested by Lisanti et al. [25]. Many forms of PLC 
have been identified in mammalian cells, of which there 
are at least 5 immunologically distinct forms and 3 have 
been sequenced and are known to be distinct gene 
products [13,26]. 
In conclusion, this study has demonstrated a role for 
G proteins, which are known activators of PLC, in 
PLAP release from tumour cells. Both insulin and EGF 
have been shown also to induce PLAP release from 
HEp-2 cells, presumably by the activation of PLC, 
although their mechanism of activation could be dif- 
ferent. 
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